119th Congress · introduced in the House · Sep 10, 2026
Dietary Supplement Innovation Act
Official title from Congress.gov
Latest action (Sep 10, 2026): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
No cosponsors.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
5 citations.
DOTERRA INTERNATIONAL LLC · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
…sues and initiatives S.3677, Dietary Supplement Listing Act of 2026, Entirety Cosmetics Regulatory Reform, Implementation related issues HSA/FSA related issues H.R.10336, Dietary Supplement Innovation Act, Entirety
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN HERBAL PRODUCTS ASSOCIATION · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Food Industry (safety, labeling, etc.)
$10,000
Paid to lobbying firm
…ion issues H.R.7366, Dietary Supplement Regulatory Uniformity Act, Entirety H.R.7407, Prohibiting Tianeptine and Other Dangerous Products Act of 2026, Entirety H.R.10336, Dietary Supplement Innovation Act, Entirety
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COUNCIL FOR RESPONSIBLE NUTRITION · lobbying firm or registrant: COUNCIL FOR RESPONSIBLE NUTRITION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$70,000
Spent on own lobbying
…ry Supplement Listing Act of 2026. Issues related to P.L. 103-417, the Dietary Supplement Health and Education Act of 1994 drug preclusion provision, including H.R. 10336, the Dietary Supplement Innovation Act of 2026. Issues related to federal preemption of state requirements applicable to dietary supplements, including H.R. 73…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · lobbying firm or registrant: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 13, 2026 · issue area: Health Issues
$146,407
Paid to lobbying firm
…Act S.3788 - CLEAR LABELS Act - Activity related to Acetaminophen use - Nonprescription Drug Product with an Additional Condition for Nonprescription Use Rule H.R. 10336 - Dietary Supplement Innovation Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHATTEM, INC D/B/A OPELLA · lobbying firm or registrant: CHATTEM, INC D/B/A OPELLA
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 6, 2026 · issue area: Health Issues
$180,000
Spent on own lobbying
…dietary supplements; Generally Recognized as Safe (GRAS); Over the Counter Monograph User Fee Act (OMUFA); Generally Recognized as Safe and Effective (GRASE); HR.10336-Dietary Supplement Innovation Act; issues related to Rx to OTC Switch/PDUFA reauthorization.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing